Eric A. Collisson, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Eric A. Collisson, MD

Assistant Professor in Residence, Department of Medicine, UCSF

eric.collisson@ucsf.edu

Phone: (415) 476-0624
Box 1270, UCSF

View on UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics» Cancer Genetics

Research Summary

I am a medical oncologist with a specific interest in the genomics of cancer. My laboratory uses a variety of techniques to interrogate three basic themes in the biology and clinical behavior of these deadly cancers: (1) intra- patient tumor heterogeneity at the temporal and anatomic levels, (2) inter-patient heterogeneity between different patients, and (3) tumor-microenvironmental interactions. We use a combination of genetically engineered mouse models, cell lines, and clinically derived samples to interrogate multiple genomic outputs with a focus on genomic DNA and mRNA.

Education

UC Berkeley, BA, 1996 Genetics
UC Los Angeles, MD, 2002, Medicine
 


Professional Experience

  • 2003-2005
    Intern and Resident, Internal Medicine, Stanford University Hospital
  • 2005-2008
    Clinical Fellowship, Heme/Onc, UCSF
  • 2008-2009
    Post Doctoral Fellow, Lawrence Berkeley National Labs
  • 2009-2010
    Instructor, Hematology/Oncology, UCSF
  • 2010-12/2012
    Asst Adj Professor, Hematology/Oncology, UCSF
  • 12/2012-present
    Asst Professor In Residence, Hematology/Oncology, UCSF

Honors & Awards

  • 1999
    Howard Hughes Medical Institute-NIH Research Scholar, Bethesda MD., Howard Hughes Medical Inst./NIH
  • 2001
    Alpha Omega Alpha, UCLA Chapter, AOA, UCLA
  • 2006
    Amgen Scholar, Amgen Foundation
  • 2007
    ASCO Young Investigator Award, American Society of Clinical Oncology
  • 2012
    AACR PanCAN Career Development Award, American Association of Cancer Research
  • 2013
    Clinical Scholar Development Award , Doris Duke Charitable Foundation

Selected Publications

  1. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One. 2015; 10(10):e0140712.
    View on PubMed
  2. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47.
    View on PubMed
  3. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc Natl Acad Sci U S A. 2015 Sep 1; 112(35):10995-1000.
    View on PubMed
  4. A MULTICENTER, OPEN-LABEL PHASE II CLINICAL TRIAL OF COMBINED MEK PLUS EGFR INHIBITION FOR CHEMOTHERAPY-REFRACTORY ADVANCED PANCREATIC ADENOCARCINOMA. Clin Cancer Res. 2015 Aug 6.
    View on PubMed
  5. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. PLoS One. 2015; 10(7):e0133219.
    View on PubMed
  6. Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course. J Natl Compr Canc Netw. 2015 Jul; 13(7):835-45.
    View on PubMed
  7. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8.
    View on PubMed
  8. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc Natl Acad Sci U S A. 2015 Jun 30; 112(26):7996-8001.
    View on PubMed
  9. Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. Cancer Discov. 2015 Aug; 5(8):850-9.
    View on PubMed
  10. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015; 15(1):206.
    View on PubMed
  11. Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. Genes Dev. 2015 Mar 15; 29(6):658-71.
    View on PubMed
  12. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6.
    View on PubMed
  13. RB and Prognosis in Resected Lung Adenocarcinoma. Clin Cancer Res. 2015 Jun 1; 21(11):2418-20.
    View on PubMed
  14. Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomes. Cell Rep. 2014 Nov 20; 9(4):1228-34.
    View on PubMed
  15. RADIA: RNA and DNA Integrated Analysis for Somatic Mutation Detection. PLoS One. 2014; 9(11):e111516.
    View on PubMed
  16. Vitamin d receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014 Sep 25; 159(1):80-93.
    View on PubMed
  17. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014 Aug 14; 158(4):929-44.
    View on PubMed
  18. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31; 511(7511):543-50.
    View on PubMed
  19. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A. 2014 Feb 18; 111(7):E748-57.
    View on PubMed
  20. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A. 2013 Nov 12; 110(46):18519-24.
    View on PubMed

Go to UCSF Profiles, powered by CTSI